The difference between information and
expert, data-driven actionable intelligence
Welcome to the January 2015 issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the January issue, and Happy New Year!
Small Molecule API Manufacturing
PharmSource has identified almost 300 contract manufacturers that can make API small molecule products. In total, these companies have operations in over 40 different countries around the world. We maintain details for most of these on their project acceptance criteria, processing capabilities and production scales, specialty chemistry services, finishing processes, regulatory approvals and other information.
Here’s a quick summary of some recent activities in the API small molecule market during Q4 2014… read on
Quality Systems, Data Integrity among Most Frequent Problems Cited by MHRA
Pharmaceutical manufacturers around the world, including CMOs, subject to inspection by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) can expect to see a more intense focus on quality systems and data integrity.
Problems related to quality systems are the most prevalent observations during inspections of pharmaceutical manufacturers, including CMOs, in the UK, according to a recent report by the Medicines and Healthcare Products Regulatory Agency (MHRA). The report was based on findings during 2013 inspections.
Over the past five years, the agency reported, the most frequently noted issues have remained consistent, except for… read on
PiSA Targeting Contract Manufacturing Opportunities
PiSA Farmaceutica is expanding its presence in contract manufacturing. The company has seven facilities manufacturing pharmaceuticals, including injectables and oral dose forms, as well plants manufacturing medical devices and wound dressings. Pharmaceutical capabilities include hormone, cephalosporin, cytotoxic and biopharmaceutical products.
According to PharmSource’s analysis, 17 Mexican companies currently offer contract manufacturing services in the country. Much of the Mexican pharma industry traditionally has focused on generics, with more than 60% of units sold within-country being generic products; this trend seems to hold true for CMOs, as well as… read on
PharmSource Trend Reports
bio/pharmaceutical sourcing and procurement executives
- Learn about trends that guide the way for optimal decision-making.
- Get data-driven market intelligence and insight from PharmSource’s experts.
Demand and Supply for Contract Manufacturing of Conventional Injectable Drugs Through 2019
Expert quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products.
List Price: US $7,500
CDMO and CRO Outlook:
Robust Market Conditions
Augur Growth, More M&A
Analyzes the factors that drive bio/pharmaceutical development spending and the demand for contract development services.
List Price: US $925
Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing
Analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry.
List Price: US $750
Contact us today for a discount when you purchase any two or more of our Trend Reports: email@example.com | +1-703-383-4903.
PharmSource STRATEGIC ADVANTAGE
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact Nathaniel Celentano at firstname.lastname@example.org / 1-703-383-4903, ext. 112 (ET USA).